Pharmaceuticals, Biotechnology and Life Sciences
Tetraphase Pharmaceuticals which creates antibiotics to treat life-threatening multidrug-resistant (MDR) infections, has gotten a licensing agreement with Everest Medicines Limited,…
Tetraphase Pharmaceuticals, a clinical-stage biopharmaceutical company said on Thursday that the Marketing Authorization Application (MAA) for IV eravacycline for the treatment of complicated intra-abdominal infections (cIAI) has been submitted and was validated by the European Medicines Agency (EMA).
Tetraphase Pharmaceuticals Inc Chief Executive Guy Macdonald said annual sales of the company’s lead experimental antibiotic for serious bacterial infections could climb as high as $700 million if approved.